Hemophilia Federation of America is a national nonprofit organization that assists, educates and advocates for the bleeding disorders community.
The following is an excerpt from a press release from Sanofi Genzyme. Read the press release in its entirety here. Sanofi and SobiTM聽announced the first patient has been dosed in the Phase 3, open-label, interventional study of BIVV001 (rFVIIIFc-VWF-XTEN), in patients with severe hemophilia A (XTEND-1 study; NCT04161495). Sobi and Sanofi are development partners for […]
Note: This is an edited form of a press release from Biogen. To read the original release in its entirety,聽click here. The first shipments of much-needed hemophilia therapy have started to arrive at treatment centers across the developing world聽Biogen,聽Swedish Orphan Biovitrum AB聽(Sobi) and the World Federation of Hemophilia (WFH) announced on Monday, October 12, 2015. […]
Note: This is an edited version of a press release from Biogen. To read the original release, click here. _____________________________________ Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE庐 [Antihemophilic Factor (Recombinant), Fc Fusion Protein] experienced low bleeding rates, Biogen and Swedish Orphan Biovitrum AB (Sobi) announced on Monday, August 10, […]
Biogen Idec and Swedish Orphan Biovitrum AB announced their intent to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. Initially, the companies have committed to donating up to 500 million IUs to the World Federation […]
Sign up for E-mails, Dateline Magazine, and other ways to stay connected.